You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Quizartinib

Showing 1 - 25 of 37
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Healthy Subjects Trial in Nottingham (Quizartinib diHCl, 14C-Quizartinib solution for infusion)

Completed
Has Results
  • Healthy Subjects
  • Quizartinib dihydrochloride
  • 14C-Quizartinib solution for infusion
  • Nottingham, United Kingdom
    Quotient Sciences
Apr 15, 2022

Healthy Subjects, Drug-drug Interaction, Pharmacokinetics Trial in San Antonio (Efavirenz, Quizartinib)

Completed
Has Results
  • Healthy Subjects
  • +3 more
  • San Antonio, Texas
    Worldwide Clinical Trials
Jun 3, 2022

Acute Myeloid Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia Trial in Houston (Decitabine, Quizartinib,

Recruiting
  • Acute Myeloid Leukemia
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
Jan 27, 2023

Acute Myeloid Leukemia Trial (Quizartinib, Treatment according to Physician's Choice, Standard of Care Chemotherapy)

Withdrawn
  • Acute Myeloid Leukemia
  • Quizartinib
  • +2 more
  • (no location specified)
May 18, 2022

Acute Myeloid Leukemia (AML) Trial in Tianjin (Quizartinib)

Completed
  • Acute Myeloid Leukemia (AML)
  • Quizartinib
  • Tianjin, China
    Institute of Hematology and Blood Diseases Hospital Chinese Acad
Jul 27, 2022

Leukemia, Myeloid, Acute Trial in United States (CPX-351, Quizartinib)

Terminated
Has Results
  • Leukemia, Myeloid, Acute
  • Denver, Colorado
  • +4 more
May 10, 2022

Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Tumor Trial in Houston (Azacitidine, Quizartinib)

Recruiting
  • Chronic Myelomonocytic Leukemia
  • +5 more
  • Houston, Texas
    M D Anderson Cancer Center
May 23, 2022

Acute Myeloid Leukemia, Blasts 20 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome Trial in

Recruiting
  • Acute Myeloid Leukemia
  • +7 more
  • Houston, Texas
    M D Anderson Cancer Center
Dec 7, 2022

FLT3 Gene Mutation Negative, FLT3 Internal Tandem Duplication Positive, Recurrent Acute Myeloid Leukemia Trial in Houston

Active, not recruiting
  • FLT3 Gene Mutation Negative
  • +7 more
  • Houston, Texas
    M D Anderson Cancer Center
Nov 16, 2022

Acute Myeloid Leukemia Trial in United States (Quizartinib, Milademetan)

Terminated
Has Results
  • Acute Myeloid Leukemia
  • Los Angeles, California
  • +7 more
Mar 14, 2022

Acute Myeloid Leukemia Trial in Tokyo (Quizartinib, Cytarabine, Idarubicin)

Completed
Has Results
  • Acute Myeloid Leukemia
  • Quizartinib
  • +3 more
  • Tokyo, Japan
    (unnamed)
Jul 26, 2021

Acute Myeloid Leukemia Trial in Worldwide (Quizartinib, Intrathecal (IT) triple chemo prophylaxis, Fludarabine)

Recruiting
  • Acute Myeloid Leukemia
  • Quizartinib
  • +4 more
  • Loma Linda, California
  • +36 more
Feb 1, 2023

Healthy Subjects, Drug-drug Interaction, Pharmacokinetics Trial in San Antonio (Dabigatran Etexilate Mesylate, Quizartinib)

Completed
Has Results
  • Healthy Subjects
  • +3 more
  • Dabigatran Etexilate Mesylate
  • Quizartinib
  • San Antonio, Texas
    Worldwide Clinical Trials
Jun 16, 2021

Hepatic Impairment, Moderate Impaired Hepatic Function Trial in Miami, Orlando (Quizartinib)

Completed
  • Hepatic Impairment
  • Moderate Impaired Hepatic Function
  • Quizartinib
  • Miami, Florida
  • +2 more
Aug 16, 2021

Acute Myeloid Leukemia Trial in Spain (Quizartinib, Fludarabine, Cytarabine)

Active, not recruiting
  • Acute Myeloid Leukemia
  • Quizartinib
  • +4 more
  • Alicante, Spain
  • +19 more
Mar 11, 2022

AML, FLT3-ITD Mutation Trial in Hong Kong (Quizartinib, Omacetaxine Mepesuccinate Injection)

Unknown status
  • AML
  • FLT3-ITD Mutation
  • Quizartinib
  • Omacetaxine Mepesuccinate Injection
  • Hong Kong, Hong Kong
    The University of Hong Kong
Dec 9, 2020

Leukemia, Myeloid, Acute, De Novo, Age More 60yr Trial in Spain (Azacitidine, Venetoclax, Quizartinib)

Recruiting
  • Leukemia, Myeloid, Acute
  • +2 more
  • Alcalá De Henares, Spain
  • +14 more
May 17, 2021

AML According to WHO 2016 Classification (Except Acute Promyelocytic Leukemia) AND (Refractory to Induction Therapy OR Relapsed

Recruiting
  • AML According to WHO 2016 Classification (Except Acute Promyelocytic Leukemia) AND (Refractory to Induction Therapy OR Relapsed After First Line Treatment)
  • MRD-triggered arm
  • Prophylactic Arm
  • Heidelberg, BW, Germany
    University Hospital Heidelberg Med5
Jan 4, 2021

Acute Myeloid Leukemia Trial in Spain (Quizartinib, Placebo oral tablet, Cytarabine)

Active, not recruiting
  • Acute Myeloid Leukemia
  • Quizartinib
  • +3 more
  • Santiago De Compostela, A Coruña, Spain
  • +44 more
Jan 20, 2022

Acute Myeloid Leukemia With Gene Mutations Trial (Quizartinib DiHCl)

No longer available
  • Acute Myeloid Leukemia With Gene Mutations
  • Quizartinib Dihydrochloride
  • (no location specified)
Apr 14, 2020

Acute Myeloid Leukemia With FLT3/ITD Mutation, Recurrent Acute Myeloid Leukemia, Refractory Acute Leukemia Trial in Houston

Recruiting
  • Acute Myeloid Leukemia With FLT3/ITD Mutation
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
May 13, 2020

Lymphoblastic Leukemia, Acute, Childhood, Myelogenous Leukemia, Acute, Childhood Trial in United States (AC220, Cytarabine,

Completed
Has Results
  • Lymphoblastic Leukemia, Acute, Childhood
  • Myelogenous Leukemia, Acute, Childhood
  • Los Angeles, California
  • +10 more
Mar 24, 2022

Leukemia, Myeloid, Acute Trial in Japan (Quizartinib)

Completed
Has Results
  • Leukemia, Myeloid, Acute
  • Quizartinib
  • Aichi, Japan
  • +26 more
Feb 4, 2020

Leukemia, Myeloid, Acute Trial in Worldwide (AC220)

Completed
Has Results
  • Leukemia, Myeloid, Acute
  • Los Angeles, California
  • +23 more
Dec 20, 2019

Acute Myeloid Leukemia, Leukemia, Myelodysplastic Syndrome Trial in Georgia, United States (AC220)

Completed
Has Results
  • Acute Myeloid Leukemia
  • +4 more
  • Birmingham, Alabama
  • +4 more
Apr 23, 2020